![Thomas Gidoin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thomas Gidoin
Director of Finance/CFO at
OSE IMMUNOTHERAPEUTICS
Profile
Thomas Gidoin is Chief Financial Officer & Deputy CEO at OSE Immunotherapeutics SA since 2026.
Formerly, Controller at Ipsen SA from 2008 to 2011, Vice President-Finance at DBV Technologies SA from 2012 to 2015, and Chief Financial Officer at Gensight Biologics SA from 2015 to 2024.
Education includes graduate degrees from Ecole Supérieure de Gestion et Finances and NEOMA Business School.
Thomas Gidoin active positions
| Companies | Position | Start |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Director of Finance/CFO | 20/08/2025 |
Former positions of Thomas Gidoin
| Companies | Position | End |
|---|---|---|
| GENSIGHT BIOLOGICS S.A. | Director of Finance/CFO | 26/01/2024 |
| DBV TECHNOLOGIES | Director of Finance/CFO | 01/01/2015 |
| IPSEN | Comptroller/Controller/Auditor | 01/01/2011 |
Training of Thomas Gidoin
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
29
1st degree connections
6
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Ipsen SA
 Ipsen SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
DBV Technologies SA
 DBV Technologies SA Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that focuses on changing the field of immunotherapy | Health Technology |
Ecole Supérieure de Gestion et Finances
 Ecole Supérieure de Gestion et Finances Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gensight Biologics SA
 Gensight Biologics SA Pharmaceuticals: MajorHealth Technology Manufactures and markets novel therapies for severe retinal neurodegenerative diseases | Health Technology |
NEOMA Business School
 NEOMA Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OSE Immunotherapeutics SA
 OSE Immunotherapeutics SA Pharmaceuticals: MajorHealth Technology Develops immunotherapy products for late-stage cancers | Health Technology |
- Stock Market
- Insiders
- Thomas Gidoin
